You are here

Alnylam (US) strikes pharma packaging deal in Flanders

Alnylam Pharmaceuticals is investing EUR 1 million in a partnership with Sharp Belgium, the Flanders-based packaging company formerly known as Enestia, Klöckner Pentapack and Budel Pack. Sharp Belgium has over 60 years of experience in pharmaceutical packaging

Pharmaceutical packaging in Flanders

Sharp Belgium, located in Flanders’ Limburg region, will package the biotech company’s products for the European market. Leveraging Flanders’ strategic location and excellent logistics system, Sharp Belgium offers many assets for Alnylam’s activities in the European market.  

Potential distribution of COVID-19 treatment

US biotech company Alnylam is specialized in RNAi therapeutics, a groundbreaking medical technology that serves as the basis for treatments that target rare diseases. Two products have already been developed, and RNAi therapy is currently being applied in the search for a medicine that prevents COVID-19 patients from infecting other people.  

Alnylam hopes to submit its case to the FDA by the end of this year. Whether the COVID-19 medicine will be packed in Flanders upon release has not been disclosed yet.  

More info

Sharp Belgium
Reported by
newspaper Het Belang van Limburg
28 August 2020

More news about Flanders?

  • Regular updates
  • No spam

Interested in doing business in Flanders?

Let us help you!

  • We can introduce you to other companies, banks and regulators
  • We organize site visits to real estate locations
  • We assist with all legal aspects of setting up a business
  • We're an official government agency
  • Our services are completely free
  • We are a team of international experts

Receive our handbook to growing your business in Flanders

  • It's completely free.
  • Get an overview of all incentives relevant to your company.
  • Tax system explained in-depth.
  • Learn how to set up your business quickly.
  • Discover the benefits of Flanders (in addition to the chocolate).

In addition to the ebook, I agree to receive one or two follow-up emails